Cellebrite

CLBT

Market cap $3.26B

Luke Lloyd isn't buying the Mag 7, arguing that there are far more attractive opportunities, such as software. “We've been buying into this software sell-off the last two or three weeks,” he says, including Reddit (RDDT), Fortinet (FTNT), and Palantir (PLTR).

TYSONS CORNER, Va. and PETAH TIKVA, Israel, Feb. 24, 2026 /PRNewswire/ -- Cellebrite (NASDAQ: CLBT), a global leader in AI-powered Digital Investigative and Intelligence solutions for the public and private sectors,  today announced the Company will participate in the upcoming Morgan Stanley Technology, Media & Telecom Conference.

Cellebrite DI Ltd. (CLBT) Q4 2025 Earnings Call Transcript

Cellebrite DI Ltd. (CLBT) came out with quarterly earnings of $0.14 per share, in line with the Zacks Consensus Estimate.

Total ARR grew 21% to $480.8 million; Revenue  grew 18% to $128.8 million Net income of $21.3 million supports non-GAAP net income of $36.7 million and adjusted EBITDA of $38.3 million, 29.8% adjusted EBITDA margin TYSONS CORNER, Va. and PETAH TIKVA, Israel, Feb. 11, 2026 /PRNewswire/ -- Cellebrite (NASDAQ: CLBT), a global leader in AI-powered Digital Investigative and Intelligence solutions for the public and private sectors, today announced financial results for the three and twelve months ending December 31, 2025.

97% cite smartphones as top evidence source, up 24 points from 2024 95% agree digital evidence increases solvability, yet 94% say complexity strains caseloads 65% believe AI can accelerate investigations, but one-third say policies prevent its use Cloud receptiveness hit 42%, yet two-thirds still rely on physical media TYSONS CORNER, Va. and PETAH TIKVA, Israel, Feb. 5, 2026 /PRNewswire/ -- Cellebrite (NASDAQ: CLBT), a global leader in AI-powered Digital Investigative and Intelligence solutions for the public and private sectors, today unveiled its 2026 Industry Trends Report, which surveyed 1,200 practitioners across 63 countries, marking the company's seventh annual report on how organizations collect, manage and analyze digital evidence.

During the quarter, we initiated new positions in nLIGHT, Guardant Health and Cellebrite. We also added to Bruker, Hexcel and Penumbra during the quarter. Along with Insmed, we also ended our investment campaigns in Integer Holdings and SharkNinja during the quarter.

TYSONS CORNER, Va. and PETAH TIKVA, Israel, Jan. 21, 2026 /PRNewswire/ -- Cellebrite (NASDAQ: CLBT), a global leader in premier Digital Investigative solutions for the public and private sectors, today announced it will report its fourth-quarter and fiscal year 2025 financial results before the U.S. markets open on Wednesday, February 11, 2026.

Norwood initiated Cellebrite position and now holds 230,671 shares, worth an estimated $4.27 million. The stake represents 3.68% of 13F reportable assets under management.

Cellebrite remains a "Buy" as federal demand rebounds and platform adoption accelerates, supporting a strong long-term growth outlook. The federal segment returned to year-over-year growth in Q3, removing the primary bear case and confirming demand was delayed, not lost. Inseyets migration and rapid cloud/SaaS ARR growth—Guardian cloud ARR up >100% for five quarters—position CLBT for outsized ARR acceleration into 2026.